Theophylline toxicity
See theophylline for general drug information.
Background
- Primarily used as a bronchodilator, however rarely used now due to better available options
- Also studied for treatment of Acute Mountain Sickness and Contrast-Induced Nephropathy
- PO available as elixer and capsule (12 or 24-hour extended release)
- IV as aminophylline (shorter acting than PO)
- Mechanism of action[1]:
- Release of endogenous catecholamines → β2 agonism → bronchodilation
- PDE inhibition → increases cAMP
- Adenosine antagonist
Clinical Features
- Cardiovascular
- Sinus Tachycardia
- Atrial/Ventricular arrhythmias
- Hypotension (2/2 β2-mediated vasodilation)
- Metabolic
- Neurologic
- Tremor
- Agitation
- Seizure
- GI
Differential Diagnosis
Evaluation
- Theophylline level
- ECG
- Metabolic panel
- Lactic acid level
- CK
Management
- Supportive care
- Cardiac monitoring
- Ondansetron (Zofran) for antiemetic
- EEG for sedated and paralyzed patients
- Cardiovascular
- IV Fluids for hypotension
- Beta blockers for tachyarrhymias
- Esmolol particularly wise first-line agent
- Controversial, involve a toxicologist
- GI decontamination (Multidose Activated Charcoal, Whole Bowel Irrigation)
- Considered in life-threatening overdose
- contraindications: unsecured airway, nausea, vomiting, ileus, Bowel Obstruction, or need for emergent endoscopy
- Considered in life-threatening overdose
- Seizures
- Dialysis
- Indicated in seizures, severe arrhythmias
- Theophylline level >90mcg/ml in acute ingestion
- Theophylline level >40mcg/ml in chronic ingestion
Disposition
Immediate release
- Home after 6 hours if:
- nontoxic
- asymptomatic
- and, normal vital sign
Sustained release
- Home after 12 hours if:
- nontoxic
- asymptomatic
- and, normal vital sign
See Also
External Links
References
- ↑ Fisher, J., & Graudins, A. (2015). Intermittent haemodialysis and sustained low-efficiency dialysis (SLED) for acute theophylline toxicity. Journal of medical toxicology : official journal of the American College of Medical Toxicology, 11(3), 359-63.
